Remedium Bio is a biotechnology company focused on developing gene therapies for musculoskeletal and age-related diseases. Their lead candidate is a single-injection gene therapy designed to reverse cartilage loss in osteoarthritis, targeting a major unmet need in rheumatology. The company leverages the clinically proven mechanism of FGF18 to promote cartilage regeneration. Founded by industry veterans, Remedium collaborates with leading researchers and medical experts to advance its innovative treatments.